Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation

OncoImmunology

Volumn 4, Issue 7, 2015, Pages 1-14

  Schilbach, Karin ^a   Alkhaled, Mohammed ^a   Welker, Christian ^a   Eckert, Franziska ^b   Blank, Gregor ^a   Ziegler, Hendrik ^a   Sterk, Marco ^a   Müller, Friederike ^a   Sonntag, Katja ^a   Wieder, Thomas ^b   Braumüller, Heidi ^b   Schmitt, Julia ^b   Eyrich, Matthias ^c   Schleicher, Sabine ^a   Seitz, Christian ^a   Erbacher, Annika ^a   Pichler, Bernd J ^b   Müller, Hartmut ^b   Tighe, Robert ^d   Lim, Annick ^e   Gillies, Stephen D ^f   Strittmatter, Wolfgang ^g   Röcken, Martin ^b   Handgretinger, Rupert ^a   more..

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d EMD Serono Research Institute Inc   (United States)

^e INSTITUT PASTEUR   (France)

^f University of Würzburg Department of Pediatrics Interdisciplinary Stem Cell Laboratory ^*  (United States)

^g Merck Serono GmbH   (Germany)

Author keywords

cancer targeted IL 12; differentiation; humanized mice; immunocytokine; immunotherapy; M1 M2 macrophages; rhabdomyosarcoma; TH1 induced senescence; TH17 cells; tumor infiltrating lymphocytes

Indexed keywords

CD40 LIGAND; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GAMMA INTERFERON; GRANZYME B; GRANZYME K; HISTONE ANTIBODY; HYBRID PROTEIN; IMMUNOCYTOKINE; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 7; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MONOCLONAL ANTIBODY; NHS 76; NHS 76 ANTIBODY-INTERLEUKIN 12 FUSION PROTEIN; RETINOID RELATED ORPHAN RECEPTOR GAMMA; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CONTROL; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; GENE EXPRESSION; HUMAN CELL; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MUSCLE DEVELOPMENT; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; RNA ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DIFFERENTIATION; TUMOR CELL INOCULATION; TUMOR IMMUNITY;

EID: 84944445823     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1014760     Document Type: Article

References (53)

1. Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MC, Meyer WH, Carli M, Anderson JR. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 2008; 26:2384-9; PMID:18467730; http://dx.doi.org/10.1200/ JCO.2007.14.7207
2. van den Broeke LT, Pendleton CD, Mackall C, Helman LJ, Berzofsky JA. Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors. Cancer Res 2006; 66:1818-23; PMID:16452243; http://dx. doi.org/10.1158/0008-5472.CAN-05-2549
3. Muller-Hermelink N, Braumuller H, Pichler B, Wieder T, Mailhammer R, Schaak K, Ghoreschi K, Yazdi A, Haubner R, Sander CA, et al. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 2008; 13:507-18; PMID:18538734; http:// dx.doi.org/10.1016/j.ccr.2008.04.001
4. Wiegering V, Eyrich M, Rutkowski S, Wolfl M, Schlegel PG, Winkler B. TH1 predominance is associated with improved survival in pediatric medulloblastoma patients. Cancer Immunol Immunother 2011; 60:693-703; PMID:21327638; http://dx.doi.org/10.1007/ s00262-011-0981-y
5. Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O, Matzinger P. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007; 109:5346-54; PMID:17327412; http://dx.doi. org/10.1182/blood-2006-10-051318
6. Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, Leonardi AJ, Morgan RA, Wang E, Marincola FM, et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 2011; 121:4746-57; PMID:22056381; http://dx.doi.org/10.1172/JCI58814
7. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994; 153:1697-706; PMID:7913943
8. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3:133-46; PMID:12563297; http:// dx.doi.org/10.1038/nri1001
9. Lee YK, Turner H, Maynard CL, Oliver JR, Chen D, Elson CO, Weaver CT. Late developmental plasticity in the T helper 17 lineage. Immunity 2009; 30:92-107; PMID:19119024; http://dx.doi.org/10.1016/j. immuni.2008.11.005
10. Lexberg MH, Taubner A, Albrecht I, Lepenies I, Richter A, Kamradt T, Radbruch A, Chang HD. IFNgamma and IL-12 synergize to convert in vivo generated Th17 into Th1/Th17 cells. Eur J Immunol 2010; 40:3017-27; PMID:21061434; http://dx.doi.org/ 10.1002/eji.201040539
11. Wigginton JM, Kuhns DB, Back TC, Brunda MJ, Wiltrout RH, Cox GW. Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity of interleukin 12 and/or interleukin 2. Cancer Res 1996; 56:1131-6; PMID:8640772
12. Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol 2009; 9:259-70; PMID:19282852; http://dx.doi.org/10.1038/nri2528
13. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010; 362:875-85; PMID:20220182; http://dx.doi.org/10.1056/ NEJMoa0905680
14. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and dendritic cells: "l'union fait la force". Blood 2005; 106:2252-8; PMID:15933055; http://dx.doi.org/10.1182/blood-2005-03-1154
15. Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 2000; 6:1678-92; PMID:10815886
16. Sharifi J, Khawli LA, Hu P, King S, Epstein AL. Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors. Hybrid Hybridomics 2001; 20:305-12; PMID:11839248; http://dx.doi.org/10.1089/ 15368590152740707
17. Chames P, Van RM, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009; 157:220-33; PMID:19459844; http://dx.doi.org/10.1111/j.1476-5381.2009.00190.x
18. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006; 311:1924-7; PMID:16484453; http://dx.doi.org/ 10.1126/science.1122927
19. Verdeil G, Marquardt K, Surh CD, Sherman LA. Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy. Proc Natl Acad Sci U S A 2008; 105:16683-8; PMID:18936481; http:// dx.doi.org/10.1073/pnas.0805054105
20. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004; 4:665-74; PMID:15343366; http://dx.doi.org/10.1038/nri1435
21. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD, King M, Mangada J, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005; 174:6477-89; PMID:15879151; http://dx.doi.org/10.4049/ jimmunol.174.10.6477
22. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9:495-502; PMID:18425106; http://dx.doi.org/10.1038/ni1581
23. BraumullerH,Wieder T, Brenner E, Aßmann S,HahnM, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013; 494:361-5; PMID:23376950; http://dx.doi.org/10.1038/nature11824
24. Saretzki G. Cellular senescence in the development and treatment of cancer. Curr Pharm Des 2010; 16:79-100; PMID:20214620; http://dx.doi.org/10.2174/ 138161210789941874
25. Zhang R, Adams PD. Heterochromatin and its relationship to cell senescence and cancer therapy. Cell Cycle 2007; 6:784-9; PMID:17377503; http://dx.doi. org/10.4161/cc.6.7.4079
26. Andres V, Walsh K.Myogenin expression, cell cycle withdrawal, and phenotypic differentiation are temporally separable events that precede cell fusion upon myogenesis. J Cell Biol 1996; 132:657-66; PMID:8647896; http://dx. doi.org/10.1083/jcb.132.4.657
27. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, Lassar AB. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995; 267:1018-21; PMID:7863327; http://dx.doi.org/10.1126/science.7863327
28. Walsh K, Perlman H. Cell cycle exit upon myogenic differentiation. Curr Opin Genet Dev 1997; 7:597-602; PMID:9388774; http://dx.doi.org/10.1016/ S0959-437X(97)80005-6
29. Paulin D, Li Z. Desmin: a major intermediate filament protein essential for the structural integrity and function of muscle. Exp Cell Res 2004; 301:1-7; PMID:15501438; http://dx.doi.org/10.1016/j. yexcr.2004.08.004
30. Carter RL, McCarthy KP, Machin LG, Jameson CF, Philp ER, Pinkerton CR. Expression of desmin and myoglobin in rhabdomyosarcomas and in developing skeletal muscle. Histopathology 1989; 15:585-95; PMID:2558065; http://dx.doi.org/10.1111/j.1365-2559.1989.tb01624.x
31. Warfel NA, El-Deiry WS. p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol 2013; 25:52-8; PMID:23159848; http://dx.doi.org/10.1097/ CCO.0b013e32835b639e
32. Schneider JW, Gu W, Zhu L, Mahdavi V, Nadal-Ginard B. Reversal of terminal differentiation mediated by p107 in Rb-/-muscle cells. Science 1994; 264:1467-71; PMID:8197461; http://dx.doi.org/ 10.1126/science.8197461
33. Takahashi A, Ohtani N, Yamakoshi K, Iida S, Tahara H, Nakayama K, Nakayama KI, Ide T, Saya H, Hara E. Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat Cell Biol 2006; 8:1291-7; PMID:17028578; http://dx.doi.org/10.1038/ncb1491
34. Billerbeck E, Kang YH, Walker L, Lockstone H, Grafmueller S, Fleming V, Flint J, Willberg CB, Bengsch B, Seigel B, et al. Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. Proc Natl Acad Sci U S A 2010; 107:3006-11; PMID:20133607; http://dx.doi.org/10.1073/ pnas.0914839107
35. Takahashi T, jbakhsh-Jones S, Strober S. Expression of CD161 (NKR-P1A) defines subsets of human CD4 and CD8 T cells with different functional activities. J Immunol 2006; 176:211-6; PMID:16365412; http://dx.doi.org/10.4049/ jimmunol.176.1.211
36. Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, Blank RB, Meylan F, Siegel R, Hennighausen L, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007; 26:371-81; PMID:17363300; http://dx.doi.org/ 10.1016/j.immuni.2007.02.009
37. Ghoreschi K, Laurence A, Yang XP, Tato CM, McGeachy MJ, Konkel JE, Ramos HL, Wei L, Davidson TS, Bouladoux N, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-βeta signalling. Nature 2010; 467:967-71; PMID:20962846; http:// dx.doi.org/10.1038/nature09447
38. Tsung K, Dolan JP, Tsung YL, Norton JA. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res 2002; 62:5069-75; PMID:12208763
39. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450:903-7; PMID:18026089; http://dx.doi.org/ 10.1038/nature06309
40. Zhang B, Karrison T, Rowley DA, Schreiber H. IFNgamma-and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest 2008; 118:1398-404; PMID:18317595; http://dx.doi.org/10.1172/JCI33522
41. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-11; PMID:11323675; http://dx.doi.org/10.1038/35074122
42. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432:307-15; PMID:15549092; http://dx.doi.org/10.1038/nature03098
43. Herbig U, Sedivy JM. Regulation of growth arrest in senescence: telomere damage is not the end of the story. Mech Ageing Dev 2006; 127:16-24; PMID:16229875; http://dx.doi.org/10.1016/j.mad.2005.09.002
44. Bothos J, Tuttle RL, Ottey M, Luca FC, Halazonetis TD. Human LATS1 is a mitotic exit network kinase. Cancer Res 2005; 65:6568-75; PMID:16061636; http://dx.doi.org/10.1158/0008-5472.CAN-05-0862
45. Gil J, Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 2006; 7:667-77; PMID:16921403; http://dx.doi.org/10.1038/nrm1987
46. Hobeika AC, Etienne W, Torres BA, Johnson HM, Subramaniam PS. IFN-gamma induction of p21 (WAF1) is required for cell cycle inhibition and suppression of apoptosis. J Interferon Cytokine Res 1999; 19:1351-61; PMID:10638704; http://dx.doi.org/ 10.1089/107999099312812
47. Huang L, Sowa Y, Sakai T, Pardee AB. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 2000; 19:5712-9; PMID:11126357; http:// dx.doi.org/10.1038/sj.onc.1203963
48. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, el-Houseini ME. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 1994; 9:3389-96; PMID:7936667
49. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9:400-14; PMID:19440234; http://dx.doi.org/10.1038/nrc2657
50. Chen X, Knowles J, Barfield RC, Kasow KA, Madden R, Woodard P, Srivastava DK, Horwitz EM, Handgretinger R, Hale GA. A novel approach for quantification of KIR expression in healthy donors and pediatric recipients of hematopoietic SCTs. Bone Marrow Transplant 2009; 43:525-32; PMID:19029967; http:// dx.doi.org/10.1038/bmt.2008.352
51. Han M, Harrison L, Kehn P, Stevenson K, Currier J, Robinson MA. Invariant or highly conserved TCR alpha are expressed on double-negative (CD3+CD4-CD8-) and CD8+ T cells. J Immunol. 1999; 163:301-11; PMID:10384129
52. Gorski J, Yassai M, Zhu X, Kissela B, Kissella B, Keever C, Flomenberg N. Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status. J Immunol 1994; 152:5109-19; PMID:8176227
53. Dechanet J, Merville P, Lim A, Retière C, Pitard V, Lafarge X, Michelson S, Méric C, Hallet MM, Kourilsky P, et al. Implication of gammadelta T cells in the human immune response to cytomegalovirus. J Clin Invest 1999; 103:437-49; PMID:10330426; http://dx. doi.org/10.1172/JCI5409